HOMEGROWN medical cannabis is now available to German patients for the first time.
Aphria RX– a wholly-owned subsidiary of Canadian pharmaceutical and cannabis company Tilray – has become the first of the three licensed German producers to achieve this significant milestone.
The medical cannabis crop is the first grown under European Good Manufacturing Practice (EU-GMP) standard in Tilray’s 6,000sq m indoor growing facility in Neumünster, about 40 miles from Hamburg.
Aphria was one of three companies, along with Aurora and Demecan, to be granted a permit by the Federal Institute for Drugs and Medical Devices (BfArM), in spring 2019, to cultivate medicinal cannabis.
Distribution of Aphria’s harvest to Germany’s pharmacies will be carried out by Frankfurt-based Cansativa. It won the the four-year contract year to become the sole distributor of all cannabis grown in Germany.
The delivery has been hailed as a ground-breaking achievement by Tilray’s International Director and Chief Strategy Officer, Denise Faltischek, who said: “Our harvest in Germany represents an important milestone in providing access to high-quality, reliable medical cannabis to patients and healthcare professionals in Germany.”